Skip to main content

Anthony D Sung

Adjunct Associate Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
Box 3961 Med Ctr, Durham, NC 27710
Cellular Therapy ABMT, Box 3961 DUMC, Durham, NC 27712

Overview


I am dedicated to the treatment of hematologic malignancies through cellular therapies such as hematopoietic stem cell transplantation (HCT). My research focuses on strategies to reduce complications of HCT and ranges from preclinical studies using murine models of HCT to Phase 1 and Phase 2 clinical trials. Areas of interest include the role of the microbiota (the trillions of bacteria living in and on our bodies), nutrition, and exercise in modulating HCT outcomes such as graft-versus-host disease (GVHD) and infections. In addition to advancing new pharmacological and cellular immunotherapies in support of these goals, we also are developing mobile health technologies (mHealth) to monitor patients at home, both as part of our innovative home transplant program as well as to improve follow up care of all our patients when they return home after transplant.

Current Duke Appointments & Affiliations


Adjunct Associate Professor of Medicine · 2024 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Senior Fellow in the Center for the Study of Aging and Human Development · 2020 - Present Center for the Study of Aging and Human Development, Institutes and Centers

Recent News Items


Published May 17, 2023
More Options for People With Blood Cancer
Published November 20, 2017
Microbe Scientists Launching Expanded Microbiome Center

View All News Items

Recent Scholarly Works


Patient-reported outcomes in clinical trials: lessons from the Blood and Marrow Transplant Clinical Trials Network.

Journal article Blood Adv · October 27, 2026 The Blood and Marrow Transplant Clinical Trials Network performs multicenter phase 2 and phase 3 clinical trials and has incorporated patient-reported outcome (PRO) measures into study protocols since its inception. As with clinical data, collection and an ... Full text Link to item Cite

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.

Journal article Sci Transl Med · October 21, 2026 Successful hematopoietic cell transplant requires immunosuppression to prevent graft-versus-host disease (GVHD), a lethal, T cell-mediated complication. The phase 3 BMT CTN 1703 trial demonstrated superior GVHD-free/relapse-free survival for posttransplant ... Full text Link to item Cite
View All Scholarly Works

Recent Grants


A Randomized Phase 2 Trial to Evaluate Prebiotic Intervention in Allogeneic Hematopoietic Stem Cell Transplantation

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2020 - 2025

Viral Oncology Training Grant

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1980 - 2025

View All Grants

Education


Harvard University · 2008 M.D.